iShares US Pharmaceuticals ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
iShares U.S. Pharmaceuticals ETF IHE
Morningstar’s Analysis IHE
Will IHE outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the IHE management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of IHE’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 77.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 24.49 | 233M | Healthcare |
Johnson & Johnson | 21.15 | 201M | Healthcare |
Royalty Pharma PLC Class A | 5.03 | 48M | Healthcare |
Viatris Inc | 4.78 | 45M | Healthcare |
Merck & Co Inc | 4.42 | 42M | Healthcare |
Pfizer Inc | 4.04 | 38M | Healthcare |
Bristol-Myers Squibb Co | 3.99 | 38M | Healthcare |
Jazz Pharmaceuticals PLC | 3.67 | 35M | Healthcare |
Elanco Animal Health Inc | 2.99 | 28M | Healthcare |
Zoetis Inc Class A | 2.92 | 28M | Healthcare |
United States